Table 2 Characteristics of reviewed studies, ordered by base year of cost data
From: Economic analyses of breast cancer control in low- and middle-income countries: a systematic review
Authors | Region / country | Base year of cost data | Study population | Breast cancer stage considered | Economic evaluation type | Study design | Perspective | Time horizon | Effectiveness outcome measure | Sources for estimation of effectiveness | Sources for estimation of resource utilization | Discount rates used | Sensitivity analysis for assumptions presented | Incremental analysis reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Groot and colleagues, 2006 [28] | World sub-regions | 2000 | Female population at risk, in AfrE, AmroA, SearD | All | Cost-effectiveness analysis | Model based | Healthcare | 100 years | DALYs | Literature based | Secondary data collection | On both costs and effects | Yes | Yes |
Okonkwo and colleagues, 2008 [30] | India | 2001 | Female population at risk | All | Cost-effectiveness analysis | Model based | Healthcare | 25 years | Life years saved | Secondary data collection | Secondary data collection | On both costs and effects | Yes | Yes |
Munshi, 2009 [41] | Worldwide | Varying from 2002 to 2007 | Breast cancer patients in general | All | Report on costs and effects separately | Other | Healthcare | NA | Intermediate outcome measures | Literature based | Literature | NA | NA | NA |
Sarvazyan and colleagues, 2008 [32] | Worldwide | Varying from 2003 to 2007 | Female population at risk | All | Cost-effectiveness analysis | Other | Not stated | 1 year | Life years saved | Literature based | Literature | NA | Yes | No |
Fonseca and colleagues, 2009 [38] | Brazil | 2005 | Hypothetical cohort of 64-year-old postmenopausal women | All | Cost-effectiveness analysis | Model based | Healthcare | Lifetime | Life years saved | Literature based | Expert opinion | On both costs and effects | Yes | Yes |
Ginsberg and colleagues, 2012 [27] | Sub-Saharan Africa and South East Asia | 2005 | Female population at risk, in SearD and AfrE | All | Cost-effectiveness analysis | Model based | Healthcare | 100 years | DALYs | Literature based | Secondary data collection | On both costs and effects | Yes | Yes |
Salomon and colleagues, 2012 [31] | Mexico | 2005 | Female population at risk | All | Cost-effectiveness analysis | Model based | Healthcare | 100 years | DALYs | Literature based | Secondary data collection | On both costs and effects | Yes | Yes |
Pakseresht and colleagues, 2011 [48] | India | 2006/2007 | 103 women with primary breast cancer in a tertiary hospital | All | Cost analysis/cost of illness | Observational | Non-healthcare | 2 years | NA | NA | Primary data collection | NA | NA | NA |
Yazihan and Yilmaz, 2006 [34] | Turkey | 2007 | Female population at risk | All | Cost-effectiveness analysis | Other | Healthcare | 6 years | DALYs | Secondary data collection | Secondary data collection | None | No | No |
Bastani and Kiadaliri, 2012 [49] | Iran | 2008 | Patients younger than 75 with node-positive breast cancer | All | Cost-utility analysis | Experimental | Healthcare | 8 months | QALYs | Primary data collection | Primary data collection | NA | No | NA |
Liubao and colleagues, 2009 [39] | China | 2008 | Model cohort of 1,000 51-year-old operable breast cancer patients | All | Cost-effectiveness analysis | Model based | Healthcare | Lifetime | QALYs | Secondary data collection | Secondary data collection | On both costs and effects | Yes | Yes |
Astim, 2011 [36] | Turkey | 2010 | Female population at risk older than 30 | All | Report on costs and effects separately | Model based | Healthcare | 10 years | Intermediate outcome measures | Secondary data collection | Literature | Yes | No | No |
Zelle and colleagues, 2012 [35] | Ghana | 2010 | Female population at risk | All | Cost-effectiveness analysis | Model based | Healthcare | 100 years | DALYs | Literature based | Primary data collection | On both costs and effects | Yes | Yes |
Bai and colleagues, 2012 [42] | China | 2012 | Model cohort of women aged 51.7, with early stage breast cancer after lumpectomy | 1 and 2 | Cost-effectiveness analysis | Model based | Healthcare | Lifetime | QALYs | Literature based | Literature/expert opinion | On both costs and effects | Yes | Yes |
Arredondo and colleagues, 1995 [43] | Brazil | Not clear | Hypothetical breast cancer case | All | Cost analysis/cost of illness | Observational | Healthcare | NA | NA | NA | Expert opinion | NA | No | No |
Boutayeb and colleagues, 2010 [37] | Morocco | Not clear | Early-stage breast cancer patients in Morocco | Not clear | Cost-effectiveness analysis | Observational | Healthcare | 1 year | Life years saved | Literature based | Secondary data collection | NA | No | No |
Denewer and colleagues, 2010 [26] | Egypt | Not clear | Female population at risk between 25 and 65 years | All | Report on costs and effects separately | Experimental | Healthcare | 2 years | Intermediate outcome measures | Primary data collection | Not clear | None | No | No |
Guggisberg and colleagues, 2011 [46] | Cameroon | Not clear | Women who underwent FNA in a rural hospital | All | Report on costs and effects separately | Observational | Healthcare | 5 weeks | Intermediate outcome measures | Primary data collection | Not clear | NA | No | No |
Kobayashi, 1988 [44] | Worldwide | Not clear | NA | NA | Cost analysis/cost of illness | Observational | Healthcare | NA | Intermediate outcome measures | Primary data collection | Primary data collection | NA | NA | NA |
Love and colleagues, 2002 [40] | Vietnam and China | Not clear | Premenopausal Vietnamese and Chinese breast cancer patients, considered for surgery | 2 | Cost-effectiveness analysis | Experimental | Healthcare | 15 years | Life years saved | Primary data collection | Not clear | On both costs and effects | No | Yes |
Mousavi and colleagues, 2008 [29] | Iran | Not clear | Female population at risk between 35 and 69 | All | Report on costs and effects separately | Other | Healthcare | 1 year | Life years saved | Expert opinion | Expert opinion | NA | No | No |
Nasrinossadat and colleagues, 2011 [47] | Iran | Not clear | 51 patients that underwent surgical excision of nonpalpable breast masses | All | Report on costs and effects separately | Observational | Healthcare | 3 to 4 years | Intermediate outcome measures | Primary data collection | Not clear | None | No | No |
Thomas and colleagues, 1999 [45] | Nigeria | Not clear | Patients who received FNA between 1994 and 1997 | All | Report on costs and effects separately | Observational | Patient | NA | Intermediate outcome measures | Primary data collection | Not clear | NA | NA | NA |